Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Guided Therapeutics (GTHP) over the last 15 years, with Q2 2025 value amounting to $8000.0.

  • Guided Therapeutics' Change in Receivables rose 36666.67% to $8000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $5000.0, marking a year-over-year increase of 22500.0%. This contributed to the annual value of -$6000.0 for FY2024, which is 30000.0% down from last year.
  • Guided Therapeutics' Change in Receivables amounted to $8000.0 in Q2 2025, which was up 36666.67% from -$1000.0 recorded in Q1 2025.
  • Guided Therapeutics' 5-year Change in Receivables high stood at $22000.0 for Q4 2021, and its period low was -$32000.0 during Q3 2022.
  • In the last 5 years, Guided Therapeutics' Change in Receivables had a median value of -$1000.0 in 2023 and averaged $769.23.
  • The largest annual percentage gain for Guided Therapeutics' Change in Receivables in the last 5 years was 60000.0% (2022), contrasted with its biggest fall of 170000.0% (2022).
  • Guided Therapeutics' Change in Receivables (Quarter) stood at $22000.0 in 2021, then tumbled by 245.45% to -$32000.0 in 2022, then soared by 112.5% to $4000.0 in 2023, then plummeted by 150.0% to -$2000.0 in 2024, then skyrocketed by 500.0% to $8000.0 in 2025.
  • Its last three reported values are $8000.0 in Q2 2025, -$1000.0 for Q1 2025, and -$2000.0 during Q4 2024.